Literature DB >> 7746977

Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes.

P F Thall1, R M Simon, E H Estey.   

Abstract

We present a Bayesian approach for monitoring multiple outcomes in single-arm clinical trials. Each patient's response may include both adverse events and efficacy outcomes, possibly occurring at different study times. We use a Dirichlet-multinomial model to accommodate general discrete multivariate responses. We present Bayesian decision criteria and monitoring boundaries for early termination of studies with unacceptably high rates of adverse outcomes or with low rates of desirable outcomes. Each stopping rule is constructed either to maintain equivalence or to achieve a specified level of improvement of a particular event rate for the experimental treatment, compared with that of standard therapy. We avoid explicit specification of costs and a loss function. We evaluate the joint behaviour of the multiple decision rules using frequentist criteria. One chooses a design by considering several parameterizations under relevant fixed values of the multiple outcome probability vector. Applications include trials where response is the cross-product of multiple simultaneous binary outcomes, and hierarchical structures that reflect successive stages of treatment response, disease progression and survival. We illustrate the approach with a variety of single-arm cancer trials, including bio-chemotherapy acute leukaemia trials, bone marrow transplantation trials, and an anti-infection trial. The number of elementary patient outcomes in each of these trials varies from three to seven, with as many as four monitoring boundaries running simultaneously. We provide general guidelines for eliciting and parameterizing Dirichlet priors and for specifying design parameters.

Entities:  

Mesh:

Year:  1995        PMID: 7746977     DOI: 10.1002/sim.4780140404

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  72 in total

1.  Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.

Authors:  Elias Jabbour; Nicholas J Short; Guillermo Montalban-Bravo; Xuelin Huang; Carlos Bueso-Ramos; Wei Qiao; Hui Yang; Chong Zhao; Tapan Kadia; Gautam Borthakur; Naveen Pemmaraju; Koji Sasaki; Zeev Estrov; Jorge Cortes; Farhad Ravandi; Yesid Alvarado; Rami Komrokji; Mikkael A Sekeres; David P Steensma; Amy DeZern; Gail Roboz; Hagop Kantarjian; Guillermo Garcia-Manero
Journal:  Blood       Date:  2017-08-03       Impact factor: 22.113

2.  High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies.

Authors:  Yago Nieto; Peter Thall; Ben Valdez; Borje Andersson; Uday Popat; Paolo Anderlini; Elizabeth J Shpall; Roland Bassett; Amin Alousi; Chitra Hosing; Partow Kebriaei; Muzaffar Qazilbash; Erin Frazier; Alison Gulbis; Christina Chancoco; Qaiser Bashir; Stefan Ciurea; Issa Khouri; Simrit Parmar; Nina Shah; Laura Worth; Gabriela Rondon; Richard Champlin; Roy B Jones
Journal:  Biol Blood Marrow Transplant       Date:  2012-05-27       Impact factor: 5.742

3.  Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi.

Authors:  Stefano Sacchi; Raffaella Marcheselli; Alessia Bari; Gabriele Buda; Anna Lia Molinari; Luca Baldini; Daniele Vallisa; Marina Cesaretti; Pellegrino Musto; Sonia Ronconi; Giorgina Specchia; Franco Silvestris; Luciano Guardigni; Angela Ferrari; Annalisa Chiapella; Angelo Michele Carella; Armando Santoro; Francesco Di Raimondo; Luigi Marcheselli; Samantha Pozzi
Journal:  Haematologica       Date:  2016-02-08       Impact factor: 9.941

4.  A new statistical method for dose-finding based on efficacy and toxicity in early phase clinical trials.

Authors:  P F Thall; E H Estey; H G Sung
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

5.  A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease.

Authors:  Mark A Schroeder; H Jean Khoury; Madan Jagasia; Haris Ali; Gary J Schiller; Karl Staser; Jaebok Choi; Leah Gehrs; Michael C Arbushites; Ying Yan; Peter Langmuir; Nithya Srinivas; Michael Pratta; Miguel-Angel Perales; Yi-Bin Chen; Gabrielle Meyers; John F DiPersio
Journal:  Blood Adv       Date:  2020-04-28

Review 6.  Statistical issues in clinical trial design.

Authors:  Kenneth R Hess
Journal:  Curr Oncol Rep       Date:  2007-01       Impact factor: 5.075

7.  Modeling and detecting potentially ruinous streaks in health expenditures.

Authors:  Joseph S Koopmeiners; Bryan E Dowd; Bradley P Carlin
Journal:  Int J Health Care Finance Econ       Date:  2007-03-10

8.  Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia.

Authors:  Marina Y Konopleva; Roland B Walter; Stefan H Faderl; Elias J Jabbour; Zhihong Zeng; Gautam Borthakur; Xuelin Huang; Tapan M Kadia; Peter P Ruvolo; Jennie B Feliu; Hongbo Lu; Lakiesha Debose; Jan A Burger; Michael Andreeff; Wenbin Liu; Keith A Baggerly; Steven M Kornblau; L Austin Doyle; Elihu H Estey; Hagop M Kantarjian
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

9.  Treatment-subgroup interaction: an example from a published, phase II clinical trial.

Authors:  Carolyn E Behrendt; Edmund A Gehan
Journal:  Contemp Clin Trials       Date:  2009-02-21       Impact factor: 2.226

10.  A Bayesian design for phase II clinical trials with delayed responses based on multiple imputation.

Authors:  Chunyan Cai; Suyu Liu; Ying Yuan
Journal:  Stat Med       Date:  2014-05-12       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.